The DOI matches its Crossref record.
Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit
Open accessAbstract
BACKGROUND: Proper sedation for neonates undergoing uncomfortable procedures may reduce stress and avoid complications. Midazolam is a short-acting benzodiazepine that is used increasingly in neonatal intensive care units (NICUs). However, its effectiveness as a sedative in neonates has not been systematically evaluated. OBJECTIVES: Primary objeciveTo assess the effectiveness of intravenous midazolam infusion for sedation, as evaluated by behavioural and/or physiological measurements of sedation levels, in critically ill neonates in the NICU. Secondary objectivesTo assess effects of intravenous midazolam infusion for sedation on complications including the following.1. Incidence of intraventricular haemorrhage (IVH)/periventricular leukomalacia (PVL).2. Mortality.3. Occurrence of adverse effects associated with the use of midazolam (hypotension, neurological abnormalities).4. Days of ventilation.5. Days of supplemental oxygen.6. Incidence of pneumothorax.7. Length of NICU stay (days).8. Long-term neurodevelopmental outcomes. SELECTION CRITERIA: We selected for review randomised and quasi-randomised controlled trials of intravenous midazolam infusion for sedation in infants aged 28 days or younger. DATA COLLECTION AND ANALYSIS: We abstracted data regarding the primary outcome of level of sedation. We assessed secondary outcomes such as intraventricular haemorrhage, periventricular leukomalacia, death, length of NICU stay and adverse effects associated with midazolam. When appropriate, we performed meta-analyses using risk ratios (RRs) and risk differences (RDs), and if the RD was statistically significant, we calculated the number needed to treat for an additional beneficial outcome (NNTB) or an additional harmful outcome (NNTH), along with their 95% confidence intervals (95% CIs) for categorical variables, and weighted mean differences (WMDs) for continuous variables. We assessed heterogeneity by performing the I-squared (I2) test. MAIN RESULTS: We included in the review three trials enrolling 148 neonates. We identified no new trials for this update. Using different sedation scales, each study showed a statistically significantly higher sedation level in the midazolam group compared with the placebo group. However, none of the sedation scales used have been validated in preterm infants; therefore, we could not ascertain the effectiveness of midazolam in this population. Duration of NICU stay was significantly longer in the midazolam group than in the placebo group (WMD 5.4 days, 95% CI 0.40 to 10.5; I2 = 0%; two studies, 89 infants). One study (43 infants) reported significantly lower Premature Infant Pain Profile (PIPP) scores during midazolam infusion than during dextrose (placebo) infusion (MD -3.80, 95% CI -5.93 to -1.67). Another study (46 infants) observed a higher incidence of adverse neurological events at 28 days' postnatal age (death, grade III or IV IVH or PVL) in the midazolam group compared with the morphine group (RR 7.64, 95% CI 1.02 to 57.21; RD 0.28, 95% CI 0.07 to 0.49; NNTH 4, 95% CI 2 to 14) (tests for heterogeneity not applicable). We considered these trials to be of moderate quality according to GRADE assessment based on the following outcomes: mortality during hospital stay, length of NICU stay, adequacy of analgesia according to PIPP scores and poor neurological outcomes by 28 days' postnatal age. AUTHORS' CONCLUSIONS: Data are insufficient to promote the use of intravenous midazolam infusion as a sedative for neonates undergoing intensive care. This review raises concerns about the safety of midazolam in neonates. Further research on the effectiveness and safety of midazolam in neonates is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2019 Update
Sweet, D. G., Carnielli, V., Greisen, G., Hallman, M., Ozek, E., te Pas, A., Plavka, R., Roehr, C. C., Saugstad, O. D., Simeoni, U., et al. (2019) · Neonatology · doi:10.1159/000499361 · Cited by 1,613
Consensus Statement for the Prevention and Management of Pain in the Newborn
Anand, K. J. S. (2001) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.155.2.173 · Cited by 789
Haddaway, N. R., Grainger, M. J., & Gray, C. T. (2022) · Research Synthesis Methods · doi:10.1002/jrsm.1563 · Cited by 604
Prevention and Management of Procedural Pain in the Neonate: An Update
COMMITTEE ON FETUS AND NEWBORN and SECTION ON ANESTHESIOLOGY AND PAIN MEDICINE, Keels, E., Sethna, N., Watterberg, K. L., Cummings, J. J., Benitz, W. E., Eichenwald, E. C., Poindexter, B. B., Stewart, D. L., Aucott, S. W., et al. (2016) · Pediatrics · doi:10.1542/peds.2015-4271 · Cited by 515
Strategies to Prevent Ventilator-Associated Pneumonia in Acute Care Hospitals: 2014 Update
Klompas, M., Branson, R., Eichenwald, E. C., Greene, L. R., Howell, M. D., Lee, G., Magill, S. S., Maragakis, L. L., Priebe, G. P., Speck, K., et al. (2014) · Infection Control & Hospital Epidemiology · doi:10.1086/677144 · Cited by 427
Metadata
- Authors
- Ng, E., Taddio, A., & Ohlsson, A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-01-31
- Volume
- 1
- Pages
- CD002052-CD002052
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2106134296
- Cited by
- 246
- References
- 0
- FWCI
- 18.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit. https://app.cochat.ai/papers/10.1002/14651858.cd002052.pub3
- The paper
- Ng, E., Taddio, A., & Ohlsson, A. (2017). Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd002052.pub3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.